CA2516836A1 - Methods of tangential flow filtration and an apparatus therefore - Google Patents
Methods of tangential flow filtration and an apparatus therefore Download PDFInfo
- Publication number
- CA2516836A1 CA2516836A1 CA002516836A CA2516836A CA2516836A1 CA 2516836 A1 CA2516836 A1 CA 2516836A1 CA 002516836 A CA002516836 A CA 002516836A CA 2516836 A CA2516836 A CA 2516836A CA 2516836 A1 CA2516836 A1 CA 2516836A1
- Authority
- CA
- Canada
- Prior art keywords
- feedstream
- milk
- filtration
- membrane
- membranes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 213
- 238000009295 crossflow filtration Methods 0.000 title claims abstract description 71
- 239000012528 membrane Substances 0.000 claims abstract description 200
- 235000013336 milk Nutrition 0.000 claims abstract description 151
- 239000008267 milk Substances 0.000 claims abstract description 151
- 210000004080 milk Anatomy 0.000 claims abstract description 151
- 238000001914 filtration Methods 0.000 claims abstract description 100
- 230000008569 process Effects 0.000 claims abstract description 90
- 239000012466 permeate Substances 0.000 claims description 137
- 238000001471 micro-filtration Methods 0.000 claims description 102
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 239000012465 retentate Substances 0.000 claims description 66
- 102000004169 proteins and genes Human genes 0.000 claims description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- 230000004907 flux Effects 0.000 claims description 53
- 239000000243 solution Substances 0.000 claims description 42
- 239000000706 filtrate Substances 0.000 claims description 35
- 238000011026 diafiltration Methods 0.000 claims description 32
- 238000000108 ultra-filtration Methods 0.000 claims description 28
- 239000000919 ceramic Substances 0.000 claims description 25
- 239000011148 porous material Substances 0.000 claims description 22
- 238000005352 clarification Methods 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 238000011012 sanitization Methods 0.000 claims description 14
- 238000005194 fractionation Methods 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims description 7
- 229960000074 biopharmaceutical Drugs 0.000 claims description 6
- 230000007704 transition Effects 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940072221 immunoglobulins Drugs 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 2
- 239000013592 cell lysate Substances 0.000 claims description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims 4
- 230000009897 systematic effect Effects 0.000 claims 4
- 239000003513 alkali Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 239000012266 salt solution Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 238000004064 recycling Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 abstract description 42
- 238000004140 cleaning Methods 0.000 abstract description 35
- 239000005018 casein Substances 0.000 abstract description 19
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 18
- 235000021240 caseins Nutrition 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 15
- 238000003860 storage Methods 0.000 abstract description 13
- 241000894006 Bacteria Species 0.000 abstract description 9
- 239000013618 particulate matter Substances 0.000 abstract description 6
- 238000013386 optimize process Methods 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 57
- 239000000047 product Substances 0.000 description 51
- 239000000523 sample Substances 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 28
- 238000012545 processing Methods 0.000 description 28
- 108010076119 Caseins Proteins 0.000 description 24
- 241000894007 species Species 0.000 description 23
- 102000011632 Caseins Human genes 0.000 description 22
- 239000012530 fluid Substances 0.000 description 22
- 239000012141 concentrate Substances 0.000 description 18
- 230000009977 dual effect Effects 0.000 description 17
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 238000011084 recovery Methods 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 238000001155 isoelectric focusing Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 230000000717 retained effect Effects 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 238000000926 separation method Methods 0.000 description 12
- 241000283707 Capra Species 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 241000283690 Bos taurus Species 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000001542 size-exclusion chromatography Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 238000005086 pumping Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- 239000000356 contaminant Substances 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 235000010633 broth Nutrition 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000010287 polarization Effects 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 108010060630 Lactoglobulins Proteins 0.000 description 4
- 102000008192 Lactoglobulins Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- -1 antibodies Proteins 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 235000020251 goat milk Nutrition 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 3
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 238000011021 bench scale process Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229940021722 caseins Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 238000013197 protein A assay Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000008234 soft water Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000010977 unit operation Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013590 bulk material Substances 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 238000011072 cell harvest Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000046101 human AFP Human genes 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 235000020004 porter Nutrition 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000693913 Homo sapiens Albumin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 101000667278 Rattus norvegicus Whey acidic protein Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003948 anatoxin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001532 anti-fungicidal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005112 continuous flow technique Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229960004336 human antithrombin iii Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000009285 membrane fouling Methods 0.000 description 1
- 238000011070 membrane recovery Methods 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000010950 spiking study Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Water Supply & Treatment (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44978603P | 2003-02-24 | 2003-02-24 | |
| US60/449,786 | 2003-02-24 | ||
| PCT/US2003/024529 WO2004076695A1 (en) | 2003-02-24 | 2003-08-06 | Methods of tangential flow filtration and an apparatus therefore |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2516836A1 true CA2516836A1 (en) | 2004-09-10 |
Family
ID=32927567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002516836A Abandoned CA2516836A1 (en) | 2003-02-24 | 2003-08-06 | Methods of tangential flow filtration and an apparatus therefore |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20040167320A1 (https=) |
| EP (1) | EP1601788A4 (https=) |
| JP (1) | JP2006515227A (https=) |
| CN (1) | CN1759189A (https=) |
| AU (1) | AU2003261387A1 (https=) |
| CA (1) | CA2516836A1 (https=) |
| RU (1) | RU2005129745A (https=) |
| WO (1) | WO2004076695A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030005468A1 (en) * | 1998-06-19 | 2003-01-02 | Meade Harry M. | Methods and vectors for improving nucleic acid expression |
| US20040226052A1 (en) * | 2000-10-13 | 2004-11-11 | Meade Harry M. | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
| WO2005073732A2 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Lc/ms method of analyzing high molecular weight proteins |
| US20050197496A1 (en) * | 2004-03-04 | 2005-09-08 | Gtc Biotherapeutics, Inc. | Methods of protein fractionation using high performance tangential flow filtration |
| EP1753999B1 (fr) * | 2004-05-28 | 2013-11-20 | Alstom Technology Ltd | Dispositif a lit fluidise a agent comburant enrichi en oxygene |
| US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| AU2011203578B2 (en) * | 2004-09-30 | 2012-10-11 | Bayer Healthcare Llc | Devices and methods for integrated continuous manufacturing of biological molecules |
| WO2006039588A2 (en) * | 2004-09-30 | 2006-04-13 | Bayer Healthcare Llc | Devices and methods for integrated continuous manufacturing of biological molecules |
| US20060130159A1 (en) * | 2004-12-09 | 2006-06-15 | Nick Masiello | Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum |
| US7531632B2 (en) * | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
| EP2007506B1 (en) * | 2006-03-31 | 2014-03-19 | Danisco US Inc. | Tangential flow filtration apparatuses, systems, and processes for the separation of compounds |
| FR2901796A1 (fr) * | 2006-05-31 | 2007-12-07 | Lab Francais Du Fractionnement | Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait |
| FR2901707B1 (fr) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| US20080160134A1 (en) * | 2006-12-27 | 2008-07-03 | Jamie Allen Hestekin | Method Of Producing Concentrated Liquid Dairy Products |
| FR2910786B1 (fr) | 2006-12-29 | 2017-08-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) | "procede d'extraction d'une proteine presente dans du lait" |
| GB0711327D0 (en) * | 2007-06-12 | 2007-07-25 | Hansa Medical Ab | Diagnostic method |
| KR101215740B1 (ko) * | 2007-07-17 | 2012-12-27 | 루드비히-막시밀리안스-우니버지테트 뮌헨 | 가변적 접선류 여과 |
| WO2009068282A1 (en) * | 2007-11-29 | 2009-06-04 | F. Hoffmann-La Roche Ag | Immunoglobulin aggregates |
| EP2293678A4 (en) * | 2008-05-14 | 2011-06-22 | Agriculture Victoria Serv Pty | ANGIOGENIC-ENRICHED MILK FRACTIONS |
| WO2009139624A1 (en) | 2008-05-15 | 2009-11-19 | Mucovax Holding B.V. | Process for producing milk fractions rich in secretory immunoglobulins |
| US9055752B2 (en) | 2008-11-06 | 2015-06-16 | Intercontinental Great Brands Llc | Shelf-stable concentrated dairy liquids and methods of forming thereof |
| CN102191226A (zh) * | 2010-03-08 | 2011-09-21 | 北京清大天一科技有限公司 | 细胞培养混合物的分离纯化方法 |
| UA112972C2 (uk) | 2010-09-08 | 2016-11-25 | Інтерконтінентал Грейт Брендс ЛЛС | Рідкий молочний концентрат з високим вмістом сухих речовин |
| KR20140093603A (ko) | 2010-12-30 | 2014-07-28 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 병원체 불활성화제로서의 글리콜 |
| US8840790B2 (en) * | 2011-04-27 | 2014-09-23 | Fenwal, Inc. | Systems and methods of controlling fouling during a filtration procedure |
| KR101993488B1 (ko) | 2011-09-01 | 2019-06-26 | 추가이 세이야쿠 가부시키가이샤 | 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법 |
| CN104583386A (zh) * | 2012-08-20 | 2015-04-29 | 泰尔茂比司特公司 | 浓缩穿过细胞生长腔室循环的流体的组分 |
| JP6345184B2 (ja) * | 2012-10-30 | 2018-06-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ２段階接線流限外濾過を使用するポリペプチドの精製 |
| US10478543B2 (en) | 2013-01-11 | 2019-11-19 | The Charles Stark Draper Laboratory, Inc. | Systems and methods for increasing convective clearance of undesired particles in a microfluidic device |
| WO2014123896A1 (en) * | 2013-02-05 | 2014-08-14 | Pocared Diagnostics Ltd. | Filter arrangement and method for using the same |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| EP3594231A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| PL3467108T3 (pl) | 2013-03-14 | 2024-09-30 | Translate Bio, Inc. | Sposoby oczyszczania informacyjnego rna |
| MX384222B (es) | 2013-07-05 | 2025-03-14 | Lab Francais Du Fractionnement | Matriz de cromatografia de afinidad. |
| EP2907565A1 (de) * | 2014-02-17 | 2015-08-19 | Bayer Technology Services GmbH | Dialyse-Einheit zum kontinuierlichen Puffer- bzw. Medienaustausch aus einer Proteinlösung |
| WO2015133972A1 (en) * | 2014-03-07 | 2015-09-11 | Agency For Science, Technology And Research | Apparatus and methods for fractionation of biological products |
| CA3140009C (en) | 2014-05-13 | 2023-09-05 | Amgen Inc. | Process control systems and methods for use with filters and filtration processes |
| SMT202000516T1 (it) | 2014-05-15 | 2020-11-10 | Insmed Inc | Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari |
| WO2015183716A1 (en) * | 2014-05-27 | 2015-12-03 | Artificial Cell Technologies, Inc. | Automated layer by layer construction of multilayer coated cores by tff |
| EP2957335B1 (en) * | 2014-06-16 | 2020-05-27 | EMD Millipore Corporation | Single-pass filtration systems and processes |
| EP4144434B1 (en) * | 2014-06-16 | 2024-04-17 | EMD Millipore Corporation | Single-pass filtration systems and processes |
| US10550148B2 (en) | 2014-06-16 | 2020-02-04 | Emd Millipore Corporation | Methods for increasing the capacity of flow-through processes |
| US10207225B2 (en) | 2014-06-16 | 2019-02-19 | Emd Millipore Corporation | Single-pass filtration systems and processes |
| JP6339674B2 (ja) | 2014-06-25 | 2018-06-06 | イー・エム・デイー・ミリポア・コーポレイシヨン | 小型スパイラル型フィルターエレメント、モジュール、およびシステム |
| CN106794295B (zh) * | 2014-08-21 | 2020-10-23 | 查尔斯斯塔克布料实验室公司 | 用于增加微流体装置中不期望的颗粒的对流清除的系统和方法 |
| US10350518B2 (en) | 2014-08-29 | 2019-07-16 | Emd Millipore Corporation | Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate |
| KR102079585B1 (ko) | 2014-08-29 | 2020-02-21 | 이엠디 밀리포어 코포레이션 | 잔류물의 재순환을 이용한 싱글 패스 접선 유동 여과 시스템 및 접선 유동 여과 시스템 |
| CN106188300A (zh) * | 2015-05-07 | 2016-12-07 | 温州市人民医院 | 一种保持胱抑素c抗体-胶乳共价偶联复合物活性的快速纯化方法 |
| PL4108769T3 (pl) | 2015-05-29 | 2024-02-05 | CureVac Manufacturing GmbH | Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN107320765A (zh) * | 2016-04-29 | 2017-11-07 | 深圳兰度生物材料有限公司 | 一种重组纤维结构胶原蛋白海绵的制备方法 |
| ES2925059T3 (es) | 2016-06-09 | 2022-10-13 | Emd Millipore Corp | Elementos de filtro de trayectoria radial, sistemas y métodos de uso de los mismos |
| BR102017001309A2 (pt) * | 2017-01-23 | 2018-08-14 | Fundação Oswaldo Cruz | vacina recombinante para helmintos em pichia pastoris, e, processos de produção e purificação de proteína como vacina para helmintos |
| WO2019084178A1 (en) * | 2017-10-24 | 2019-05-02 | Cerahelix, Inc. | SYSTEMS AND METHODS FOR MULTI-STAGE FLUID SEPARATION |
| CN107907643A (zh) * | 2017-11-10 | 2018-04-13 | 福建省水产研究所 | 一种测定天然海水中溶解相、纳米相和真溶液相中有机碳和无机氮含量的方法 |
| CN110241012B (zh) * | 2018-03-09 | 2022-11-01 | 嘉和生物药业有限公司 | 一种生物大分子上游分阶段截留的生产方法、生产模块及在生产中的应用 |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| WO2019213398A1 (en) | 2018-05-02 | 2019-11-07 | Insmed Incorporated | Methods for the manufacture of liposomal drug formulations |
| EP3794013B1 (en) * | 2018-05-17 | 2024-02-21 | CSL Behring AG | Method and system of protein extraction |
| EP3917646A4 (en) * | 2019-01-30 | 2022-03-23 | Repligen Corporation | METHOD OF USE OF NUCLEAR MEMBRANES FOR THE FILTRATION OF BIOLOGICAL FLUIDS |
| CN110607272B (zh) * | 2019-09-23 | 2022-11-01 | 山东甲骨文生物科技有限公司 | 一种哺乳动物细胞培养液的添加剂及细胞培养液 |
| WO2021064053A1 (en) * | 2019-10-01 | 2021-04-08 | Tetra Laval Holdings & Finance S.A. | A method for filtering a dairy product |
| EP4061826A1 (en) * | 2019-11-20 | 2022-09-28 | CSL Behring AG | Method for extracting a protein from a precipitate and method for precipitating impurities |
| CN111018968B (zh) * | 2019-12-16 | 2021-07-27 | 兴盟生物医药(苏州)有限公司 | 一种通过超滤浓缩制备高浓度抗体制剂的方法 |
| WO2021252782A1 (en) * | 2020-06-11 | 2021-12-16 | 2Seventy Bio, Inc. | Methods for manufacturing viral vectors |
| CN113713621B (zh) * | 2021-08-26 | 2022-08-02 | 杭州纽创生物检测有限公司 | 一种应用于病毒的sptff装置、灌注系统及病毒料液过滤方法 |
| CN116328553A (zh) * | 2022-11-16 | 2023-06-27 | 安徽百奥秘科生物医药研究院有限公司 | 一种过滤膜及一步过滤快速提取核酸装置及提取核酸方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888115A (en) * | 1983-12-29 | 1989-12-19 | Cuno, Incorporated | Cross-flow filtration |
| US4874516A (en) * | 1984-12-29 | 1989-10-17 | Ngk Insulators, Ltd. | A ceramic filter for semi-ultrafiltration |
| US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
| US5256294A (en) * | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
| SE470375B (sv) * | 1992-05-07 | 1994-02-07 | Alfa Laval Food Eng Ab | Sätt att erhålla högvärdiga proteinprodukter ur vassle |
| US5356651A (en) * | 1992-12-30 | 1994-10-18 | Pall Corporation | Manufacturing method for producing sterile milk using dynamic microfiltration |
| US5518624A (en) * | 1994-05-06 | 1996-05-21 | Illinois Water Treatment, Inc. | Ultra pure water filtration |
| US5585466A (en) * | 1994-12-06 | 1996-12-17 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Crystals of serum albumin for use in genetic engineering and rational drug design |
| US6268487B1 (en) * | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
| GB9807464D0 (en) * | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
| AU756832B2 (en) * | 1999-02-22 | 2003-01-23 | Ncsrt, Inc. | Purification of biological substances |
| US6984378B1 (en) * | 1999-02-26 | 2006-01-10 | Pfizer, Inc. | Method for the purification, recovery, and sporulation of cysts and oocysts |
-
2003
- 2003-08-06 CA CA002516836A patent/CA2516836A1/en not_active Abandoned
- 2003-08-06 CN CN03826243.6A patent/CN1759189A/zh active Pending
- 2003-08-06 AU AU2003261387A patent/AU2003261387A1/en not_active Abandoned
- 2003-08-06 JP JP2004568846A patent/JP2006515227A/ja not_active Abandoned
- 2003-08-06 RU RU2005129745/13A patent/RU2005129745A/ru not_active Application Discontinuation
- 2003-08-06 EP EP03816097A patent/EP1601788A4/en not_active Withdrawn
- 2003-08-06 US US10/635,117 patent/US20040167320A1/en not_active Abandoned
- 2003-08-06 WO PCT/US2003/024529 patent/WO2004076695A1/en not_active Ceased
-
2005
- 2005-07-21 US US11/191,280 patent/US20050260672A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006515227A (ja) | 2006-05-25 |
| AU2003261387A1 (en) | 2004-09-17 |
| WO2004076695A1 (en) | 2004-09-10 |
| RU2005129745A (ru) | 2006-03-20 |
| US20040167320A1 (en) | 2004-08-26 |
| EP1601788A1 (en) | 2005-12-07 |
| CN1759189A (zh) | 2006-04-12 |
| US20050260672A1 (en) | 2005-11-24 |
| EP1601788A4 (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040167320A1 (en) | Methods of tangential flow filtration and an apparatus therefore | |
| US20050197496A1 (en) | Methods of protein fractionation using high performance tangential flow filtration | |
| EP1991063B1 (en) | Clarification of transgenic milk using depth filtration | |
| DK2550971T3 (en) | Devices and methods for integrated continuous production of biological molecules | |
| CA2254871C (en) | Purification of biologically active peptides from milk | |
| US11117929B2 (en) | Purification of an agent of interest | |
| CN114829371A (zh) | 使用透析过滤缓冲液强化的病毒过滤 | |
| CN101027080A (zh) | 用高效切向流过滤进行蛋白质分级的方法 | |
| AU2011203578B2 (en) | Devices and methods for integrated continuous manufacturing of biological molecules | |
| HK1090670A (en) | Methods of tangential flow filtration and an apparatus therefore |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |